Vaccines are biological entity used to activate acquired immunity to control or prevent particular disease or a group of disease. Immunization is carried out in infants as well as in adults. Vaccination against various bacterial and viral diseases is an integral part of infectious disease control world-wide.
The global Disease Control and Prevention Vaccine market is projected to reach US$ 84190 million in 2029, increasing from US$ 41900 million in 2022, with the CAGR of 10.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Disease Control and Prevention Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Disease Control and Prevention Vaccine market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
Segment by Type
Live-Attenuated
Inactivated
Recombinant Sub Unit and Toxoid
Segment by Application
Pediatric Vaccine
Adult Vaccine
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Disease Control and Prevention Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Disease Control and Prevention Vaccine 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Live-Attenuated
1.2.3 Inactivated
1.2.4 Recombinant Sub Unit and Toxoid
1.3 麻豆原创 by Application
1.3.1 Global Disease Control and Prevention Vaccine 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pediatric Vaccine
1.3.3 Adult Vaccine
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Disease Control and Prevention Vaccine 麻豆原创 Perspective (2018-2029)
2.2 Disease Control and Prevention Vaccine Growth Trends by Region
2.2.1 Global Disease Control and Prevention Vaccine 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Disease Control and Prevention Vaccine Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Disease Control and Prevention Vaccine Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Disease Control and Prevention Vaccine 麻豆原创 Dynamics
2.3.1 Disease Control and Prevention Vaccine Industry Trends
2.3.2 Disease Control and Prevention Vaccine 麻豆原创 Drivers
2.3.3 Disease Control and Prevention Vaccine 麻豆原创 Challenges
2.3.4 Disease Control and Prevention Vaccine 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Disease Control and Prevention Vaccine Players by Revenue
3.1.1 Global Top Disease Control and Prevention Vaccine Players by Revenue (2018-2023)
3.1.2 Global Disease Control and Prevention Vaccine Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Disease Control and Prevention Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Disease Control and Prevention Vaccine Revenue
3.4 Global Disease Control and Prevention Vaccine 麻豆原创 Concentration Ratio
3.4.1 Global Disease Control and Prevention Vaccine 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Disease Control and Prevention Vaccine Revenue in 2022
3.5 Disease Control and Prevention Vaccine Key Players Head office and Area Served
3.6 Key Players Disease Control and Prevention Vaccine Product Solution and Service
3.7 Date of Enter into Disease Control and Prevention Vaccine 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Disease Control and Prevention Vaccine Breakdown Data by Type
4.1 Global Disease Control and Prevention Vaccine Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Disease Control and Prevention Vaccine Forecasted 麻豆原创 Size by Type (2024-2029)
5 Disease Control and Prevention Vaccine Breakdown Data by Application
5.1 Global Disease Control and Prevention Vaccine Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Disease Control and Prevention Vaccine Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Disease Control and Prevention Vaccine 麻豆原创 Size (2018-2029)
6.2 North America Disease Control and Prevention Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2018-2023)
6.4 North America Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Disease Control and Prevention Vaccine 麻豆原创 Size (2018-2029)
7.2 Europe Disease Control and Prevention Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2018-2023)
7.4 Europe Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Disease Control and Prevention Vaccine 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Disease Control and Prevention Vaccine 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Disease Control and Prevention Vaccine 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Disease Control and Prevention Vaccine 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Disease Control and Prevention Vaccine 麻豆原创 Size (2018-2029)
9.2 Latin America Disease Control and Prevention Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Disease Control and Prevention Vaccine 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Disease Control and Prevention Vaccine 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Disease Control and Prevention Vaccine 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Disease Control and Prevention Vaccine Introduction
11.1.4 GSK Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.1.5 GSK Recent Development
11.2 Merck & Co., Inc
11.2.1 Merck & Co., Inc Company Detail
11.2.2 Merck & Co., Inc Business Overview
11.2.3 Merck & Co., Inc Disease Control and Prevention Vaccine Introduction
11.2.4 Merck & Co., Inc Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.2.5 Merck & Co., Inc Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Disease Control and Prevention Vaccine Introduction
11.3.4 Pfizer Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Disease Control and Prevention Vaccine Introduction
11.4.4 Sanofi Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 AstraZeneca PLC
11.5.1 AstraZeneca PLC Company Detail
11.5.2 AstraZeneca PLC Business Overview
11.5.3 AstraZeneca PLC Disease Control and Prevention Vaccine Introduction
11.5.4 AstraZeneca PLC Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.5.5 AstraZeneca PLC Recent Development
11.6 Sinovac Biotech Ltd
11.6.1 Sinovac Biotech Ltd Company Detail
11.6.2 Sinovac Biotech Ltd Business Overview
11.6.3 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Introduction
11.6.4 Sinovac Biotech Ltd Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.6.5 Sinovac Biotech Ltd Recent Development
11.7 Astellas Pharma Inc
11.7.1 Astellas Pharma Inc Company Detail
11.7.2 Astellas Pharma Inc Business Overview
11.7.3 Astellas Pharma Inc Disease Control and Prevention Vaccine Introduction
11.7.4 Astellas Pharma Inc Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.7.5 Astellas Pharma Inc Recent Development
11.8 Serum Institute of India Pvt. Ltd
11.8.1 Serum Institute of India Pvt. Ltd Company Detail
11.8.2 Serum Institute of India Pvt. Ltd Business Overview
11.8.3 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Introduction
11.8.4 Serum Institute of India Pvt. Ltd Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.8.5 Serum Institute of India Pvt. Ltd Recent Development
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Company Detail
11.9.2 Daiichi Sankyo Business Overview
11.9.3 Daiichi Sankyo Disease Control and Prevention Vaccine Introduction
11.9.4 Daiichi Sankyo Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.9.5 Daiichi Sankyo Recent Development
11.10 Abbott Laboratories
11.10.1 Abbott Laboratories Company Detail
11.10.2 Abbott Laboratories Business Overview
11.10.3 Abbott Laboratories Disease Control and Prevention Vaccine Introduction
11.10.4 Abbott Laboratories Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.10.5 Abbott Laboratories Recent Development
11.11 Bharat Biotech International
11.11.1 Bharat Biotech International Company Detail
11.11.2 Bharat Biotech International Business Overview
11.11.3 Bharat Biotech International Disease Control and Prevention Vaccine Introduction
11.11.4 Bharat Biotech International Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.11.5 Bharat Biotech International Recent Development
11.12 Bavarian Nordic A/S
11.12.1 Bavarian Nordic A/S Company Detail
11.12.2 Bavarian Nordic A/S Business Overview
11.12.3 Bavarian Nordic A/S Disease Control and Prevention Vaccine Introduction
11.12.4 Bavarian Nordic A/S Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.12.5 Bavarian Nordic A/S Recent Development
11.13 CSL Limited
11.13.1 CSL Limited Company Detail
11.13.2 CSL Limited Business Overview
11.13.3 CSL Limited Disease Control and Prevention Vaccine Introduction
11.13.4 CSL Limited Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.13.5 CSL Limited Recent Development
11.14 Emergent BioSolutions Inc
11.14.1 Emergent BioSolutions Inc Company Detail
11.14.2 Emergent BioSolutions Inc Business Overview
11.14.3 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Introduction
11.14.4 Emergent BioSolutions Inc Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.14.5 Emergent BioSolutions Inc Recent Development
11.15 Inovio Pharmaceuticals Inc
11.15.1 Inovio Pharmaceuticals Inc Company Detail
11.15.2 Inovio Pharmaceuticals Inc Business Overview
11.15.3 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Introduction
11.15.4 Inovio Pharmaceuticals Inc Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.15.5 Inovio Pharmaceuticals Inc Recent Development
11.16 Johnson & Johnson
11.16.1 Johnson & Johnson Company Detail
11.16.2 Johnson & Johnson Business Overview
11.16.3 Johnson & Johnson Disease Control and Prevention Vaccine Introduction
11.16.4 Johnson & Johnson Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.16.5 Johnson & Johnson Recent Development
11.17 Mitsubishi Tanabe Pharma Corporation
11.17.1 Mitsubishi Tanabe Pharma Corporation Company Detail
11.17.2 Mitsubishi Tanabe Pharma Corporation Business Overview
11.17.3 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Introduction
11.17.4 Mitsubishi Tanabe Pharma Corporation Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.17.5 Mitsubishi Tanabe Pharma Corporation Recent Development
11.18 Novavax Inc
11.18.1 Novavax Inc Company Detail
11.18.2 Novavax Inc Business Overview
11.18.3 Novavax Inc Disease Control and Prevention Vaccine Introduction
11.18.4 Novavax Inc Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.18.5 Novavax Inc Recent Development
11.19 Panacea Biotec Ltd
11.19.1 Panacea Biotec Ltd Company Detail
11.19.2 Panacea Biotec Ltd Business Overview
11.19.3 Panacea Biotec Ltd Disease Control and Prevention Vaccine Introduction
11.19.4 Panacea Biotec Ltd Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.19.5 Panacea Biotec Ltd Recent Development
11.20 Takeda Pharmaceutical Company Limited
11.20.1 Takeda Pharmaceutical Company Limited Company Detail
11.20.2 Takeda Pharmaceutical Company Limited Business Overview
11.20.3 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Introduction
11.20.4 Takeda Pharmaceutical Company Limited Revenue in Disease Control and Prevention Vaccine Business (2018-2023)
11.20.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
听
听
*If Applicable.